It’s About Time Healthcare Had a Geek Squad

 

As healthcare embraces technological innovation, could bringing a Geek Squad service approach from companies like Best Buy Health lead this transformation? The sector is witnessing a seismic shift with the integration of advanced technology and home-based care. Gastroenterological issues have surged by 20% in the past decade, highlighting the need for this tech-driven approach to diagnosis and treatment.

The crucial question in this dynamic is: How can tech support services akin to a Geek Squad change the face of healthcare delivery and management, particularly in gastroenterology?

On today’s episode of Healthcare Rethink, a FinThrive podcast, the spotlight shines on Best Buy Health’s methodical fusion of technology into healthcare. Host Brian Urban engages with Ben Zaniello, MD MPH, the Chief Medical Officer at Best Buy Health, in a discussion that promises to unravel how technology can lead to unprecedented improvements in patient outcomes and the overall healthcare experience.

Main Points of Conversation:

  • Exploring the pivotal role of Best Buy Health in pioneering patient-focused technology
  • Examining the transformative effects of telehealth on managing chronic conditions
  • Assessing the potential of AI and in-home technological advancements in early disease detection and ongoing health monitoring

Dr. Ben Zaniello is a pioneer in healthcare technology and the Chief Medical Officer at Best Buy Health. His impressive career, interwoven with significant medical practice and innovation, is marked by his education from prestigious institutions and numerous accolades in the field of medical technology.

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…